Skip to content
SPC Logo

Viagra 25mg, 50mg, 100mg

Last Updated on eMC 23-Jun-2016 View document  | Pfizer Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 23-Jun-2016 and displayed until Current

Reasons for adding or updating:

  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 01-Jun-2016

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



The SPC has been updated as follows:

Section 10: The revision date has been updated to June 2016 in line with the date of the EMA approved annexes.

Updated on 12-Oct-2015 and displayed until 23-Jun-2016

Reasons for adding or updating:

  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Date of revision of text on the SPC: 01-Oct-2015

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



The SPC has been updated as follows:

On 3rd July 2015 Pfizer received a communication from the EMA informing us in advance of the publication of the minutes of June 2015 PRAC Plenary, of a PRAC recommendation applicable to tadalafil and all other authorised phosphodiesterase type 5 (PDE5) inhibitors with regards to the need to include a contraindication in the Product information of all authorised PDE5 inhibitors in view of the identified safety issue of the concomitant administration of Adempas (riociguat) and PDE5 inhibitors.

Updates have been made to the  SmPC sections 4.3 and 4.5, and section 2 of the PIL in line with the PRAC recommendation. In addition the SmPC & PIL have been aligned to the EU QRD 9.1 template. Other minor editorial/formatting revisions have also been made.

Updated on 25-Jun-2015 and displayed until 12-Oct-2015

Reasons for adding or updating:

  • Change to section 4.8 - Undesirable effects - how to report a side effect
  • Change to section 5.2 - Pharmacokinetic properties

Date of revision of text on the SPC: 01-Jun-2015

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



Section 5.2: correction of values:

"In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased by 200% and 79% respectively."

Section 4.8: removal of the following sentence:

"In addition, the frequency of medically important adverse reactions reported from post marketing experience is included as not known."

In addition the opportunity is being taken to remove an * incorrectly included in Section 4.8 of the 100 mg tablets SPC for "Transient ischaemic attack"

Updated on 01-May-2015 and displayed until 25-Jun-2015

Reasons for adding or updating:

  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text
  • Change to section 6.5 - Nature and contents of container

Date of revision of text on the SPC: 01-Apr-2015

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



The SPC has been updated as follows

Addition of 24 pack size for the 50mg & 100mg strengths only.
SPC sections impacted are 6.5, 8 & 10.

Updated on 11-Dec-2014 and displayed until 01-May-2015

Reasons for adding or updating:

  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 01-Oct-2014

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

date of revision of text

Updated on 02-Sep-2014 and displayed until 11-Dec-2014

Reasons for adding or updating:

  • Change to section 4.8 - Undesirable effects - how to report a side effect

Date of revision of text on the SPC: 01-Aug-2014

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

Section 4.8 of the SPC has been updated to change the ADR reporting details from the IMB to the HPRA.

Updated on 28-Apr-2014 and displayed until 02-Sep-2014

Reasons for adding or updating:

  • Change to section 4.8 - Undesirable effects

Date of revision of text on the SPC: 03-Mar-2014

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



Section 4.8 of the SPC has been updated following a review of the clinical trial data to re-assess the estimated frequencies of adverse drug reactions.

Updated on 05-Mar-2014 and displayed until 28-Apr-2014

Reasons for adding or updating:

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Date of revision of text on the SPC: 01-Jan-2014

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

Section 4.4  additional information regarding priapism 
Section 4.5 update to effects of other medicines on sildenafil

Updated on 29-Aug-2013 and displayed until 05-Mar-2014

Reasons for adding or updating:

  • Change to section 4.4 - Special warnings and precautions for use

Date of revision of text on the SPC: 25-Jul-2013

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

Update to section 4.4  revise the information on acute NAION based on new data coming from the clinical study

Updated on 23-Apr-2013 and displayed until 29-Aug-2013

Reasons for adding or updating:

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.5 - Nature and contents of container
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 17-Apr-2013

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



Sections 2, 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2, 5.3, 6.5, 9 & 10 have been revised. The changes are concerned with updates to headings, formatting and additional information for sections 4.6 and 5.1.

Updated on 28-Jan-2013 and displayed until 23-Apr-2013

Reasons for adding or updating:

  • Change to section 4.8 - Undesirable effects

Date of revision of text on the SPC: 01-Jan-2013

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

Update to include the ADRs haematuria, haematospermia and penile haemorrhage in the section 4.8 of the SmPC of Viagra.

Updated on 19-Jul-2010 and displayed until 28-Jan-2013

Reasons for adding or updating:

  • Change to section 4.8 - Undesirable Effects

Date of revision of text on the SPC: 01-Jul-2010

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



Addition of

Severe Cutaneous Adverse Reactions (SCAR) to Section 4.8

 

 

Updated on 23-Feb-2009 and displayed until 19-Jul-2010

Reasons for adding or updating:

  • Change to section 10 date of revision of the text

Date of revision of text on the SPC: 29-Jan-2009

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



Section 10 – date of revision updated

Updated on 18-Sep-2008 and displayed until 23-Feb-2009

Reasons for adding or updating:

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable Effects
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form

Date of revision of text on the SPC: 01-Aug-2008

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



Section 2: Administrative change

Section 3: Administrative change

Section 4.2: Update to use in children to include adolescents

Section 4.8: Reformatted. Somnolence, hypoaesthesia, atrial fibrillation, vertigo, tinnitus, nausea, dry mouth, lacrimation disorders added.

Updated on 26-Mar-2008 and displayed until 18-Sep-2008

Reasons for adding or updating:

  • Change to section 4.8 - Undesirable Effects

Date of revision of text on the SPC: 01-Mar-2008

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

 

4.8 inclusion of updated post-marketing surveillance information regarding hearing loss/sudden deafness.

Updated on 27-Nov-2007 and displayed until 26-Mar-2008

Reasons for adding or updating:

  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)

Date of revision of text on the SPC: 01-Jun-2006

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

6.5 – details of 1 pack size removed

8.0 – details of 1 pack size removed

Updated on 23-Oct-2007 and displayed until 27-Nov-2007

Reasons for adding or updating:

  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)

Date of revision of text on the SPC: 01-Jun-2006

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

8.  Marketing authorisation numbers for the 2 pack size added

Updated on 11-Jul-2006 and displayed until 23-Oct-2007

Reasons for adding or updating:

  • Change to section 4.3 - Contra-indications

Date of revision of text on the SPC: 01-Jun-2006

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

Change to 4.3   Contra-indications

Updated on 29-Nov-2005 and displayed until 11-Jul-2006

Reasons for adding or updating:

  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 10 (date of (partial) revision of the text

Updated on 10-May-2005 and displayed until 29-Nov-2005

Reasons for adding or updating:

  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.4 - Special Warnings and Precautions for Use

Updated on 01-Mar-2005 and displayed until 10-May-2005

Reasons for adding or updating:

  • Correction of spelling/typing errors

Updated on 07-Sep-2004 and displayed until 01-Mar-2005

Reasons for adding or updating:

  • Change to section 6. 5 - Nature and Contents of Container

Updated on 21-Jun-2004 and displayed until 07-Sep-2004

Reasons for adding or updating:

  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 9 - Date of Renewal of Authorisation
  • Change to section 10 (date of (partial) revision of the text

Updated on 20-Nov-2003 and displayed until 21-Jun-2004

Reasons for adding or updating:

  • Change to section 2 - qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic Indications
  • Change to section 4.3 - Contra-indications
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 (date of (partial) revision of the text

Updated on 01-Sep-2003 and displayed until 20-Nov-2003

Reasons for adding or updating:

  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 6. 5 - Nature and Contents of Container
  • Correction of spelling/typing errors

Updated on 29-May-2002 and displayed until 01-Sep-2003

Reasons for adding or updating:

  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 (date of (partial) revision of the text

Updated on 17-Dec-2001 and displayed until 29-May-2002

Reasons for adding or updating:

  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 6. 3 - Shelf Life
  • Change to section 10 (date of (partial) revision of the text

Updated on 13-Sep-2001 and displayed until 17-Dec-2001

Reasons for adding or updating:

  • Removal of Black Triangle

Updated on 20-Aug-2001 and displayed until 13-Sep-2001

Reasons for adding or updating:

  • Transferred from eMC version 1

Updated on 16-Oct-2000 and displayed until 20-Aug-2001

Reasons for adding or updating:

  • No reasons supplied

Updated on 09-Mar-2000 and displayed until 16-Oct-2000

Reasons for adding or updating:

  • No reasons supplied

Updated on 04-Feb-2000 and displayed until 09-Mar-2000

Reasons for adding or updating:

  • No reasons supplied

Updated on 06-Sep-1999 and displayed until 04-Feb-2000

Reasons for adding or updating:

  • No reasons supplied

Company contact details

Pfizer Limited

Company image
Address

Ramsgate Road, Sandwich, Kent, CT13 9NJ

Fax

+44 (0)1304 656 221

Telephone

+44 (0)1304 616 161

Medical Information Website

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

sildenafil citrate

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue